562 related articles for article (PubMed ID: 30573992)
1. The clinical promise of immunotherapy in triple-negative breast cancer.
Vikas P; Borcherding N; Zhang W
Cancer Manag Res; 2018; 10():6823-6833. PubMed ID: 30573992
[TBL] [Abstract][Full Text] [Related]
2. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
3. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
[TBL] [Abstract][Full Text] [Related]
6. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
[TBL] [Abstract][Full Text] [Related]
7. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
Front Oncol; 2022; 12():779786. PubMed ID: 35646659
[TBL] [Abstract][Full Text] [Related]
8. Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer.
Jacobs F; Agostinetto E; Miggiano C; De Sanctis R; Zambelli A; Santoro A
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296893
[TBL] [Abstract][Full Text] [Related]
9. Research advances and new challenges in overcoming triple-negative breast cancer.
Zong Y; Pegram M
Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC?
Zhou Y; Tian Q; Wang BY; Yang J; Zhao SD; Yang J
Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2885-2897. PubMed ID: 33877653
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
13. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).
Blackley EF; Loi S
Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159
[TBL] [Abstract][Full Text] [Related]
14. Augmentation of antitumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade.
Song H; Wang H; Gong M; Wu L; Liu X; Cao W; Gao X; Dou R; Chen Q; Hu H
Cell Biol Int; 2022 Feb; 46(2):278-287. PubMed ID: 34854515
[TBL] [Abstract][Full Text] [Related]
15. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
[TBL] [Abstract][Full Text] [Related]
16. Progress and challenges of immunotherapy in triple-negative breast cancer.
Zhu Y; Zhu X; Tang C; Guan X; Zhang W
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188593. PubMed ID: 34280474
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials of immunotherapy in triple-negative breast cancer.
Howard FM; Pearson AT; Nanda R
Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
20. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
